United BioPharma UB-921 granted approval from TFDA for Phase I clinical trial of breast cancer treatment

Share Button

United Biopharma (UBP, 6471) today announced that the Taiwan Food and Drug Administration (TFDA) has approved the company’s application to conduct a phase I clinical trial of UB-921 for the treatment of HER2-positive breast cancer.

The phase I trial of UB-921 is designed to evaluate the safety, tolerability and pharmacokinetics of the drug on healthy volunteers.

Traditional chemotherapy for cancers works on inhibiting cell division and DNA synthesis of the tumor cells, however, the anti-cancer drugs not only attack the tumor cells but also kill the normal cells, resulting in considerable side effects. The biopharmaceutical, monoclonal antibodies (mAbs) therapeutics such as Herceptin® work like a magic bullet, targeting the antigens dysregulated in cancers, and therefore generate more significant efficacy with limited side effects.

In the United States alone, 1 in 8 women (about 12%) will develop invasive breast cancer over the course of her lifetime. In 2017, an estimated 252,710 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S. Herceptin® is one of the top-selling drugs with 2016 global sales of US$6.8 billion.

UB-921 is a biosimilar candidate of Herceptin® (Trastuzumab) that targets the HER2 receptor, a protein found in high quantities on the outside of cells in HER2-positive cancers. The pre-clinical studies, including anti-proliferation assay, pharmacokinetics study in rats, toxicology testing in non-human primates and in vivo tumor growth inhibition assay, showed that UB-921 has highly comparable characteristics with its reference product Herceptin®.

About United BioPharma (6471)

United BioPharma (UBP) was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnering with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs, to improve the health of mankind. For more information, please visit http://www.unitedbiopharma.com

United BioPharma Forward-Looking Statements

The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.

 

 

Contact:

Victor Run-Ben Sun

Spokesperson and Vice President of Public Affairs

+886-978-067-006

PR@unitedbiopharma.com

victor.sun@unitedbiopharma.com

Share Button
本篇發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟。將永久鏈結加入書籤。

發表迴響

你的電子郵件位址並不會被公開。

你可以使用這些 HTML 標籤與屬性: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>